Cardiome Enters BRINAVESS Distribution Agreement With Nomeco A/S In Denmark

February 18, 2014


VANCOUVER, Feb. 18, 2014 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME)
(TSX: COM) today announced that its subsidiary, Correvio GmbH, has
entered into an agreement with Nomeco A/S, headquartered in Copenhagen,
Denmark, to distribute BRINAVESS(TM) (vernakalant IV) to customers in the
Danish market.

“We are pleased to have entered into this distribution agreement with
Nomeco,” said Karim Lalji, Cardiome’s Chief Commercial Officer. “In
addition to allowing Cardiome to work with one of the strongest
hospital pharmaceutical logistics provider in Denmark, this agreement
satisfies the requirements that will enable the timely shipment of
BRINAVESS to Cardiome’s customers and rapidly fulfil their orders.”

“We are excited to be working with Cardiome to distribute BRINAVESS to
our network of hospital customers nationwide,” said Søren Vesti
Esbensen, Nomeco’s Head of Commercial Affairs. “Our logistics and
dedicated customer service team is ready to support BRINAVESS and
ensure complete customer satisfaction along every step of the ordering
and shipping process.”

Financial details of the agreement have not been disclosed.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a specialty pharmaceutical company dedicated to
the development and commercialization of cardiovascular therapies that
will improve the quality of life and health of patients suffering from
heart disease. Cardiome has two marketed, in-hospital, cardiology
products, BRINAVESS(TM) (vernakalant IV), approved in Europe and other
territories for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl)
a reversible GP IIb/IIIa inhibitor indicated for use in Acute Coronary
Syndrome patients.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto
Stock Exchange (COM). For more information, please visit our web site
at www.cardiome.com.

About Nomeco A/S

Nomeco is Denmark’s largest pharmaceutical wholesaler and an
international competency center for the pharmaceutical industry. At
Nomeco we specialize in health logistics. We ensure that the Danish
population always has timely access to pharmaceuticals. This goal is
realized via a value adding partnership with pharmacies, hospitals and
the pharmaceutical industry – a partnership based on security,
confidence and a high level of ethics. Nomeco is undergoing constant
development in close contact with the market and authorities. This
development rests on a solid base of knowledge and values. Nomeco is a
Danish company deeply rooted in the pharmaceutical industry while at
the same time being part of an international organization.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
“believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”,
“intend”, “expect” and similar expressions. Forward- looking
statements may involve, but are not limited to, comments with respect
to our objectives and priorities for the remainder of 2013 and beyond,
our strategies or future actions, our targets, expectations for our
financial condition and the results of, or outlook for, our operations,
research and development and product and drug development. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
events or developments to be materially different from any future
results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and
other factors are taken into account as part of our assumptions
underlying these forward-looking statements and include, among others,
the following: general economic and business conditions in the United
States, Canada, Europe, and the other regions in which we operate;
market demand; technological changes that could impact our existing
products or our ability to develop and commercialize future products;
competition; existing governmental legislation and regulations and
changes in, or the failure to comply with, governmental legislation and
regulations; availability of financial reimbursement coverage from
governmental and third-party payers for products and related
treatments; adverse results or unexpected delays in pre-clinical and
clinical product development processes; adverse findings related to the
safety and/or efficacy of our products or products; decisions, and the
timing of decisions, made by health regulatory agencies regarding
approval of our technology and products; the requirement for
substantial funding to expand commercialization activities; and any
other factors that may affect our performance. In addition, our
business is subject to certain operating risks that may cause any
results expressed or implied by the forward-looking statements in this
presentation to differ materially from our actual results. These
operating risks include: our ability to attract and retain qualified
personnel; our ability to successfully complete pre-clinical and
clinical development of our products; changes in our business strategy
or development plans; intellectual property matters, including the
unenforceability or loss of patent protection resulting from
third-party challenges to our patents; market acceptance of our
technology and products; our ability to successfully manufacture,
market and sell our products; the availability of capital to finance
our activities; and any other factors described in detail in our
filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to
place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary
statement. All forward-looking statements and information made herein
are based on our current expectations and we undertake no obligation to
revise or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp.

Source: PR Newswire

comments powered by Disqus